Last updated: July 12, 2026
Yasmin (drospirenone/ethinyl estradiol) Investment Scenario and Fundamentals Analysis (Patent, Exclusivity, Generics, and Revenue Exposure)
Executive summary: YASMIN (drospirenone 3 mg / ethinyl estradiol 0.03 mg) is a mature, off-patent oral contraceptive in the US with extensive generic availability and no current, material US patent-driven exclusivity barrier. Investment upside in the brand rests on continued payer/formulary positioning and supply stability, not on sustained exclusivity. Key risk is rapid price erosion and margin compression once additional generics or authorized generics expand. For new entrants, the dominant pathway is generic ANDA, with limited product-differentiation scope and manufacturing/IP barriers largely confined to remaining formulation, packaging, and process patents, which are typically weak or already expired for this class.
What is YASMIN and how does it drive earnings for investors?
YASMIN is a combined oral contraceptive (COC) containing:
- Drospirenone 3 mg
- Ethinyl estradiol 0.03 mg
Commercial fundamentals for COCs tend to be dominated by:
- PBM and formulary contracting (brand vs generic mix)
- Wholesale acquisition cost and rebate dynamics
- Channel inventory cycles and pricing response to generic entry
- Prescription persistence in a crowded therapeutic category
Investment implication: For a brand COC, the “fundamentals” are less about clinical differentiation and more about margin protection through contracting and inventory control, with long-term returns capped by ongoing generic competition.
When does YASMIN lose exclusivity in the US, and when can generics enter?
Featured snippet answer: YASMIN’s core brand exclusivity has effectively ended; the US market is already populated by multiple generic drospirenone/ethinyl estradiol products, meaning new generic entry is no longer an “either/or” event but a continuous competitive supply cycle.
Exclusivity categories that matter for COCs
- Orange Book patent listings: govern patent infringement risk for ANDA filers.
- TE exclusivity (5 years) and pediatric exclusivity: generally not relevant to long-established COCs, which have long since entered generic eras.
- Orphan exclusivity: not applicable.
Practical consequence: any remaining patent estate, if present, is unlikely to prevent ANDA entry at this stage absent a currently listed, unexpired, enforceable patent covering a specific NDA/strength/dosage form.
What patents protect YASMIN, and how many are still enforceable?
Featured snippet answer: For established COCs like YASMIN, the enforceable patent set in the Orange Book is typically limited, expired, or close to expiry, and the market largely operates under generic competition.
Patent estate mapping (what investors should check)
For a complete investor-grade patent picture, the relevant buckets in the Orange Book are:
- Composition of matter (often expired for older COCs)
- Method-of-use (coverage may be weak for classic contraception indications)
- Formulation patents (may be fewer and narrower)
- Process and manufacturing (often less defensible for a simple tablet product)
- Packaging and device (rare for standard tablets)
Investment implication: even if some patents remain listed, they usually do not change the economics unless they are (1) clearly unexpired, (2) actively litigated, and (3) can block generic approval through successful 180-day exclusivity or injunction leverage. In mature COCs, that combination is uncommon.
What is the Orange Book status of YASMIN (NDA listings, listed patents, and expiries)?
Featured snippet answer: YASMIN is expected to have extensive Orange Book coverage historically, but the current market structure indicates that the brand’s main commercial exclusivity has already been overcome by generic ANDAs.
What matters for diligence and deal work
Investors and licensors should focus on:
- Number of Orange Book patents currently listed
- Earliest expiration date among those patents
- Whether patents are delisted or expired
- Whether any patent is the subject of recent Paragraph IV litigation
Practical consequence: when Orange Book listings no longer restrict ANDA approval, the market becomes a pure pricing contest.
How strong is the patent estate for drospirenone/ethinyl estradiol COCs?
Featured snippet answer: Patent strength in this space is typically low for blocking generic competition at the brand level in the long run because:
- key compositions and classic dosing regimens are older,
- ANDA approvals are usually feasible after patent expiry, and
- litigation, when it occurs, is often resolved into settlement and continued generic entry.
What “weak vs strong” looks like in COCs
- Strong: multiple unexpired, broad claims; ongoing district court injunction activity; intact pediatric/TE gating.
- Weak: narrow formulation/process claims; no current injunction; routine ANDA clearance.
Investment implication: expect limited capacity for royalty uplift or licensing leverage unless there is an active enforcement cycle, which is not a typical driver for mature COCs.
Are there Paragraph IV challenges for YASMIN generics, and who files?
Featured snippet answer: For YASMIN, generic presence indicates that earlier ANDA/PIV challenges have already produced approvals, and the marginal incremental driver now is new entrants securing shelf space rather than major Paragraph IV-driven market disruption.
What investors should track
- ANDA applicants for each strength and pack configuration
- Court dockets for Paragraph IV settlements and consent decrees
- 180-day exclusivity triggers (often diluted by multiple filers)
Investment implication: new Paragraph IV filings are less likely to produce sustained price premiums after the class is already broadly generic.
What generic entry risks exist for YASMIN (new ANDAs, authorized generics, 180-day exclusivity)?
Featured snippet answer: The primary generic risk is margin compression from continued supply expansion. 180-day exclusivity is usually not a one-time, brand-defining event at this point.
Risk map for pricing and volume
- Authorized generics (if any): can undercut price quickly and reduce brand volume.
- Additional generic shelves: PBMs can increase substitution.
- Consolidation and supply concentration: can stabilize prices short term but can introduce manufacturing contingency risk.
Investment implication: monitor supplier counts per NDC, availability metrics, and contract terms. Brand protection is structural only if inventory supply and PBM economics favor the brand.
What formulation patents protect YASMIN, and do they create real barriers?
YASMIN is a standard tablet COC. For this product class, formulation patents usually cover:
- specific tablet composition parameters,
- dissolution profile targets,
- excipient systems,
- or manufacturing-controlled attributes.
Commercial reality: even if such patents exist, the generic manufacturing ecosystem for oral contraceptive tablets is mature, and practical barriers come from whether a claim is enforceable and whether ANDA filers can design around.
Investment implication: formulation patents rarely justify a brand’s long-term valuation in already-generic COCs unless there is active, near-term litigation that impacts launch timing.
What method-of-use patents exist for YASMIN, and how do they affect generics?
Method-of-use coverage for classic contraceptive use cases typically faces:
- claim specificity limits,
- difficulty proving induced infringement for standard labeling,
- and a shrinking window once generic labeling can be carved to non-covered regimens.
Investment implication: for a mature contraception brand, method-of-use patents are usually not the primary driver of launch delays.
What patent litigation affects YASMIN (district courts, settlements, consent decrees)?
Featured snippet answer: Given ongoing generic availability, YASMIN is not currently characterized by a dominant, ongoing injunction-driven litigation posture that would be expected to support sustained premium pricing for the brand.
Litigation outcomes that matter economically
- settlement agreements that fix launch dates,
- consent decrees limiting “at-risk” launches,
- changes in labeling to avoid claim coverage,
- dismissal of remaining claims.
Investment implication: absent active litigation that limits ANDA supply, the investment case should focus on brand contracting and supply dynamics rather than expecting legal holdback.
How does YASMIN compare with other drospirenone/ethinyl estradiol COCs (Alesse/others) in market risk?
Within COCs, the key competitive comparisons are not necessarily brand-to-brand clinical differences but:
- switchability by prescribers to other drospirenone-based products,
- therapeutic equivalence and interchangeability for payers,
- formulary tier placement.
Investment implication: the relevant competitive set is the full drospirenone/EE and alternative COC class. Even if one brand has better rebates, generic substitution reduces long-run pricing power.
What is YASMIN’s FDA regulatory status and pathway relevance (NDA vs ANDA landscape)?
YASMIN is an FDA-approved branded product. For investors:
- the regulatory risk is less about approval delay,
- more about postmarketing compliance, labeling updates, and supply chain stability.
Pathway relevance:
- Generics compete through ANDA for the same dosage form and strength.
- Bioequivalence is typically not a high technical hurdle for established oral tablets.
Investment implication: regulatory changes rarely create a durable moat for mature COCs; compliance and supply are the ongoing operational risks.
Which companies control the generic market for drospirenone/ethinyl estradiol, and how does that affect pricing?
Pricing power in generics typically depends on:
- number of suppliers by NDC,
- contract concentration with PBMs,
- and manufacturing capacity.
Investment implication: when generic supply is fragmented, price erosion is faster. When supply consolidates, prices can stabilize but volatility increases with manufacturing outages.
Revenue exposure: what portion of growth or profit depends on YASMIN vs the class?
For an investor scenario, COC brand revenues typically behave like:
- stable base volume with declining unit share,
- rebate-driven gross-to-net adjustments,
- and periodic “catch-up” cycles when competing supplies go out of stock.
Investment implication: if valuation depends on YASMIN outperforming the generic price curve, the thesis must rest on contracting (higher gross margin per Rx), not on exclusivity.
How would a new entrant monetize drospirenone/ethinyl estradiol COCs today?
A new entrant’s monetization levers:
- obtaining ANDA approval promptly after patent barriers clear,
- selecting pack sizes and NDCs to win PBM preference,
- competing on cost-of-goods and reliability,
- negotiating tier placement through rebate strategy.
Investment implication: investment returns will be driven by launch speed, manufacturing efficiency, and contracting, not by IP defensibility.
Key Takeaways
- YASMIN is a mature COC in a structurally generic category in the US; the investment story is driven by PBM contracting, rebate economics, and supply stability, not by long-lived exclusivity.
- Patent and exclusivity barriers that could support premium pricing are typically expired or narrow at this stage, and broad barriers to ANDA entry are not consistent with the observed market reality of multiple generics.
- The dominant commercial risk for the brand is continued generic competition leading to margin compression.
- The dominant opportunity, if any, comes from formulary positioning and supply continuity, which can temporarily stabilize share and pricing.
FAQs
1) Can a generic still be blocked from launching YASMIN in the US?
Only if there is an unexpired, enforceable Orange Book patent specifically covering the ANDA product configuration, and the ANDA is launched “at risk” in a way that triggers infringement outcomes.
2) What does “weak patent estate” mean for a COC investment case?
It typically means that remaining claims are narrow, largely design-aroundable, and not tied to active, injunction-capable litigation that would materially delay generic supply.
3) How do PBM rebates change YASMIN profitability as generics expand?
Rebate pressure generally increases as generic substitution rises, compressing gross-to-net and unit economics unless the brand secures a durable formulary tier.
4) What operational events can move YASMIN share even without new IP?
Manufacturing outages, inventory shortages, and pack-size availability can shift demand despite therapeutic equivalence.
5) What diligence checklist best predicts YASMIN pricing trajectory?
Track NDC-level generic supplier counts, PBM formulary tiering changes, gross-to-net trends, and wholesale availability, then map those to any remaining Orange Book listings with the earliest expiry dates.
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. ANDA Information and Drug Approval Process. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
- FDA. Drugs@FDA: Product Details for NDA Applications. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
